发明申请
US20110223628A1 METHOD FOR THE IDENTIFICATION OF A RISK FOR A THROMBOGENIC DISORDER BY DETERMINING THE TAFl-lle347 POLYMORPHISM
失效
通过确定TAF1-lle347多态性鉴定致病性疾病风险的方法
- 专利标题： METHOD FOR THE IDENTIFICATION OF A RISK FOR A THROMBOGENIC DISORDER BY DETERMINING THE TAFl-lle347 POLYMORPHISM
- 专利标题（中）： 通过确定TAF1-lle347多态性鉴定致病性疾病风险的方法
-
申请号： US13109111申请日： 2011-05-17
-
公开(公告)号： US20110223628A1公开(公告)日： 2011-09-15
- 发明人: Detlef KOZIAN , Stefan SCHAEFER , Bernward SCHOELKENS , Karl-Ernst SIEGLER , Jean-Francois DELEUZE , Sylvain RICARD , Sandrine MACE
- 申请人： Detlef KOZIAN , Stefan SCHAEFER , Bernward SCHOELKENS , Karl-Ernst SIEGLER , Jean-Francois DELEUZE , Sylvain RICARD , Sandrine MACE
- 申请人地址： DE Frankfurt am Main
- 专利权人： SANOFI-AVENTIS DEUTSCHLAND GMBH
- 当前专利权人： SANOFI-AVENTIS DEUTSCHLAND GMBH
- 当前专利权人地址： DE Frankfurt am Main
- 优先权： EP03026030.1 20031112
- 主分类号： C12Q1/37
- IPC分类号： C12Q1/37
摘要：
The present invention is directed to a method identifying a risk for a thrombogenic disorder including, without limitation, atrial fibrillation, stroke, prolonged intermitted neurological deficit (PRIND), transitory ischemic attack (TIA), atherosclerotic cerebrovascular disease (CVD) and/or coronary heart disease, as well as to a method for selecting patients with a risk for a thrombogenic disorder, to a method for identifying a pharmaceutical for the therapy or prophylaxis of a thrombogenic disorder as well as to a method for producing a medicament and a diagnostic by employing the TAFI-Ile347 polymorphism.